8I7 Stock Overview
A biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Gemina Laboratories Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.45 |
| 52 Week High | CA$0.45 |
| 52 Week Low | CA$0.17 |
| Beta | 0.095 |
| 11 Month Change | 159.30% |
| 3 Month Change | 65.19% |
| 1 Year Change | 75.59% |
| 33 Year Change | 72.87% |
| 5 Year Change | n/a |
| Change since IPO | 48.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8I7 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 31.2% | -0.7% | -0.02% |
| 1Y | 75.6% | -17.2% | 8.2% |
Return vs Industry: 8I7 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 8I7 exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| 8I7 volatility | |
|---|---|
| 8I7 Average Weekly Movement | 24.3% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 8I7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 8I7's weekly volatility has increased from 16% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 6 | Brian Firth | www.geminalabs.com |
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops LEGIO X COVID-19, a COVID-19 rapid antigen test; and LEGIO X Influenza AB, an influenza AB multiplex lateral flow test. It is developing respiratory syncytial virus and tuberculosis.
Gemina Laboratories Ltd. Fundamentals Summary
| 8I7 fundamental statistics | |
|---|---|
| Market cap | €46.11m |
| Earnings (TTM) | -€2.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-18.0x
P/E RatioIs 8I7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8I7 income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$3.72m |
| Earnings | -CA$3.72m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -42.1% |
How did 8I7 perform over the long term?
See historical performance and comparison